JP2004509061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004509061A5 JP2004509061A5 JP2001559475A JP2001559475A JP2004509061A5 JP 2004509061 A5 JP2004509061 A5 JP 2004509061A5 JP 2001559475 A JP2001559475 A JP 2001559475A JP 2001559475 A JP2001559475 A JP 2001559475A JP 2004509061 A5 JP2004509061 A5 JP 2004509061A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- hepatitis
- virus
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 241000711549 Hepacivirus C Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 Ｃ型肝炎ウイルス（ＨＣＶ）感染症またはＢ型肝炎ウイルス（ＨＢＶ）感染症の処置のための医薬の製造における、式１：
【化１】
（式中、該化合物はＤ−配置である）
で示されるカルボキサミジンまたはその医薬的に許容し得る塩の使用。
【請求項２】 医薬的に許容し得る塩は式１で示される塩酸塩である、請求項１記載の使用。
【請求項３】 ウイルス感染症はＨＣＶ感染症である、請求項１または２のいずれかに記載の使用。
【請求項４】 医薬は経口投与用に製剤化される、請求項１〜３のいずれか１つに記載の使用。
【請求項５】 医薬は、化合物の用量を患者の体重ｋｇ当たり０．１ｍｇ〜患者の体重ｋｇ当たり４０ｍｇの間を含むように製剤化する、請求項１〜４のいずれか１つに記載の使用。
【請求項６】 医薬は更にインターフェロンを含む、請求項１〜５のいずれか１つに記載の使用。
【請求項７】 インターフェロンはインターフェロン−αである、請求項６記載の使用。
【請求項８】 式１：
【化２】
で示されるカルボキサミジンまたはその医薬的に許容し得る塩、および１つ以上の医薬的に許容し得る添加物を含有する、Ｃ型肝炎ウイルス（ＨＣＶ）感染症またはＢ型肝炎ウイルス（ＨＢＶ）感染症の処置のための医薬組成物であって、
該医薬組成物は固形の経口用製剤である、該医薬組成物。
【請求項９】 医薬的に許容し得る塩は式１で示される塩酸塩である、請求項８記載の医薬組成物。
【請求項１０】 医薬組成物は経口投与用に製剤化される、請求項８または９のいずれかに記載の医薬組成物。
【請求項１１】 医薬組成物は固形製剤である、請求項１０記載の医薬組成物。
【請求項１】 Ｃ型肝炎ウイルス（ＨＣＶ）感染症またはＢ型肝炎ウイルス（ＨＢＶ）感染症の処置のための医薬の製造における、式１：
【化１】
で示されるカルボキサミジンまたはその医薬的に許容し得る塩の使用。
【請求項２】 医薬的に許容し得る塩は式１で示される塩酸塩である、請求項１記載の使用。
【請求項３】 ウイルス感染症はＨＣＶ感染症である、請求項１または２のいずれかに記載の使用。
【請求項４】 医薬は経口投与用に製剤化される、請求項１〜３のいずれか１つに記載の使用。
【請求項５】 医薬は、化合物の用量を患者の体重ｋｇ当たり０．１ｍｇ〜患者の体重ｋｇ当たり４０ｍｇの間を含むように製剤化する、請求項１〜４のいずれか１つに記載の使用。
【請求項６】 医薬は更にインターフェロンを含む、請求項１〜５のいずれか１つに記載の使用。
【請求項７】 インターフェロンはインターフェロン−αである、請求項６記載の使用。
【請求項８】 式１：
【化２】
該医薬組成物は固形の経口用製剤である、該医薬組成物。
【請求項９】 医薬的に許容し得る塩は式１で示される塩酸塩である、請求項８記載の医薬組成物。
【請求項１０】 医薬組成物は経口投与用に製剤化される、請求項８または９のいずれかに記載の医薬組成物。
【請求項１１】 医薬組成物は固形製剤である、請求項１０記載の医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18267600P | 2000-02-15 | 2000-02-15 | |
| US60/182,676 | 2000-02-15 | ||
| US09/595,365 | 2000-06-16 | ||
| US09/595,365 US6455508B1 (en) | 2000-02-15 | 2000-10-05 | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
| PCT/US2001/040148 WO2001060379A1 (en) | 2000-02-15 | 2001-02-15 | Nucleoside analogs with carboxamidine modified monocyclic base |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009018382A Division JP5253204B2 (ja) | 2000-02-15 | 2009-01-29 | カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004509061A JP2004509061A (ja) | 2004-03-25 |
| JP2004509061A5 true JP2004509061A5 (ja) | 2006-01-05 |
| JP4975930B2 JP4975930B2 (ja) | 2012-07-11 |
Family
ID=26878297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001559477A Pending JP2004510691A (ja) | 2000-02-15 | 2001-02-15 | カルボキサミジンで修飾した二環式塩基を有するヌクレオシドアナログ |
| JP2001559475A Expired - Fee Related JP4975930B2 (ja) | 2000-02-15 | 2001-02-15 | カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ |
| JP2009018382A Expired - Fee Related JP5253204B2 (ja) | 2000-02-15 | 2009-01-29 | カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001559477A Pending JP2004510691A (ja) | 2000-02-15 | 2001-02-15 | カルボキサミジンで修飾した二環式塩基を有するヌクレオシドアナログ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009018382A Expired - Fee Related JP5253204B2 (ja) | 2000-02-15 | 2009-01-29 | カルボキサミジンで修飾した単環式塩基を有するヌクレオシドアナログ |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6455508B1 (ja) |
| EP (3) | EP1257281B8 (ja) |
| JP (3) | JP2004510691A (ja) |
| KR (2) | KR20030005190A (ja) |
| CN (2) | CN1268335C (ja) |
| AT (1) | ATE377422T1 (ja) |
| AU (2) | AU3845001A (ja) |
| BR (2) | BR0108402A (ja) |
| CA (2) | CA2399208C (ja) |
| CY (1) | CY1107103T1 (ja) |
| CZ (2) | CZ302327B6 (ja) |
| DE (1) | DE60131250T8 (ja) |
| DK (1) | DK1257281T3 (ja) |
| ES (2) | ES2528429T3 (ja) |
| HK (1) | HK1051149A1 (ja) |
| HR (2) | HRP20020583A2 (ja) |
| HU (2) | HU229480B1 (ja) |
| IL (3) | IL150555A0 (ja) |
| MX (2) | MXPA02007931A (ja) |
| NO (2) | NO329927B1 (ja) |
| NZ (2) | NZ521390A (ja) |
| PL (2) | PL365239A1 (ja) |
| PT (1) | PT1257281E (ja) |
| RS (1) | RS20090086A (ja) |
| RU (2) | RU2259831C2 (ja) |
| SI (2) | SI21076A (ja) |
| SK (2) | SK287765B6 (ja) |
| WO (2) | WO2001060381A1 (ja) |
| YU (1) | YU61502A (ja) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
| US7638496B2 (en) * | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EP1736478B1 (en) * | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
| EP1539188B1 (en) | 2001-01-22 | 2015-01-07 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2003037908A1 (en) * | 2001-10-31 | 2003-05-08 | Ribapharm Inc. | Antiviral combination therapy and compositions |
| MXPA04012802A (es) | 2002-06-28 | 2005-04-19 | Idenix Cayman Ltd | Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae. |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| MXPA05005192A (es) | 2002-11-15 | 2005-09-08 | Idenix Cayman Ltd | Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae. |
| CA2509687C (en) | 2002-12-12 | 2012-08-14 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
| WO2004084796A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset Ltd. | Compounds for the treatment of flaviviridae infections |
| US20040197292A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| US20040197287A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| US20040202636A1 (en) * | 2003-04-11 | 2004-10-14 | Kaczvinsky Joseph Robert | Personal care composition containing an antidandruff component and a nonionic surfactant |
| US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
| US20050009848A1 (en) * | 2003-07-10 | 2005-01-13 | Icn Pharmaceuticals Switzerland Ltd. | Use of antivirals against inflammatory bowel diseases |
| WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| US20050095218A1 (en) * | 2003-10-29 | 2005-05-05 | The Procter & Gamble Company | Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| JP5055564B2 (ja) | 2004-06-15 | 2012-10-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのｃ−プリンヌクレオシド類似体 |
| JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
| EP1879607B1 (en) | 2005-05-02 | 2014-11-12 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Ｈｃｖ ｎｓ３蛋白酶抑制劑 |
| JP4705984B2 (ja) | 2005-08-01 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド |
| ES2422290T3 (es) | 2005-12-23 | 2013-09-10 | Idenix Pharmaceuticals Inc | Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados |
| US8497292B2 (en) | 2005-12-28 | 2013-07-30 | Translational Therapeutics, Inc. | Translational dysfunction based therapeutics |
| WO2007123579A2 (en) * | 2005-12-28 | 2007-11-01 | Translational Therapeutics | Translational dysfunction based therapeutics |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
| WO2008051477A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| KR101615500B1 (ko) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Ｈｃｖ ｎｓ3 프로테아제 억제제 |
| CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
| GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| AU2007335962B2 (en) | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
| GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| RU2466729C2 (ru) * | 2006-12-28 | 2012-11-20 | Айденикс Фармасьютикалз, Инк. | Соединения и фармацевтические композиции для лечения вирусных инфекций |
| WO2009010785A1 (en) | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
| EP2271345B1 (en) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| CN102159285B (zh) | 2008-07-22 | 2014-05-14 | 默沙东公司 | 作为hcv ns3蛋白酶抑制剂的大环喹喔啉化合物 |
| WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
| GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
| US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
| US9328138B2 (en) | 2011-11-15 | 2016-05-03 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
| US20140356325A1 (en) | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
| CN102978264B (zh) * | 2012-11-14 | 2014-12-10 | 广东肇庆星湖生物科技股份有限公司 | 一种他立韦林的制备方法 |
| WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
| CN114404427A (zh) | 2014-02-13 | 2022-04-29 | 配体药物公司 | 前药化合物及其用途 |
| US9994600B2 (en) | 2014-07-02 | 2018-06-12 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| EP3331895B1 (en) | 2015-08-06 | 2020-07-29 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
| EP3684771A1 (en) | 2017-09-21 | 2020-07-29 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7-(3,4-DIHYDROXY-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-2-METHYL-7H-PYRROLO[2,3-d]PYRIMIDINE-5-CARBOXAMIDE AND USES THEREOF |
| EP3737676B1 (en) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| US3991078A (en) | 1971-06-01 | 1976-11-09 | Icn Pharmaceuticals, Inc. | N-substituted 1,2,4-triazoles |
| US3984396A (en) | 1971-06-01 | 1976-10-05 | Icn Pharmaceuticals, Inc. | 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters |
| USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US3962211A (en) * | 1975-01-13 | 1976-06-08 | The University Of Utah | 7-substituted nucleoside compounds |
| US4093624A (en) | 1977-01-31 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 1,2,4-Thiadiazolidine-3,5-dione |
| JPS6426593A (en) | 1987-07-21 | 1989-01-27 | Asahi Glass Co Ltd | Nucleoside derivative |
| US4892865A (en) * | 1987-12-01 | 1990-01-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents |
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| HU220105B (hu) * | 1996-01-23 | 2001-10-28 | Icn Pharmaceuticals, Inc. | Ribavirin alkalmazása TH1- és TH2- válaszreakció befolyásolására szolgáló készítmények előállítására |
| IL129126A0 (en) * | 1996-10-16 | 2000-02-17 | Icn Pharmaceuticals | Monocyclic l-nucleosides analogs and uses thereof |
| EP1212326A4 (en) * | 1999-08-27 | 2003-08-20 | Icn Pharmaceuticals | NUCLEOSIDE ANALOGS OF PYRROLO 2,3-d] PYRIMIDINE |
-
2000
- 2000-10-05 US US09/595,365 patent/US6455508B1/en not_active Expired - Lifetime
-
2001
- 2001-02-15 KR KR1020027010593A patent/KR20030005190A/ko not_active Application Discontinuation
- 2001-02-15 WO PCT/US2001/005172 patent/WO2001060381A1/en active Search and Examination
- 2001-02-15 EP EP01920996A patent/EP1257281B8/en not_active Expired - Lifetime
- 2001-02-15 NZ NZ521390A patent/NZ521390A/en unknown
- 2001-02-15 IL IL15055501A patent/IL150555A0/xx unknown
- 2001-02-15 SI SI200120010A patent/SI21076A/sl not_active IP Right Cessation
- 2001-02-15 AU AU38450/01A patent/AU3845001A/en not_active Abandoned
- 2001-02-15 JP JP2001559477A patent/JP2004510691A/ja active Pending
- 2001-02-15 CZ CZ20022798A patent/CZ302327B6/cs not_active IP Right Cessation
- 2001-02-15 SI SI200120011A patent/SI21077A/sl not_active IP Right Cessation
- 2001-02-15 EP EP07107588.1A patent/EP1813278B9/en not_active Expired - Lifetime
- 2001-02-15 BR BR0108402-0A patent/BR0108402A/pt not_active Application Discontinuation
- 2001-02-15 RU RU2002120922/15A patent/RU2259831C2/ru active
- 2001-02-15 DK DK01920996T patent/DK1257281T3/da active
- 2001-02-15 CA CA2399208A patent/CA2399208C/en not_active Expired - Fee Related
- 2001-02-15 HU HU0300027A patent/HU229480B1/hu unknown
- 2001-02-15 RU RU2002120483/14A patent/RU2002120483A/ru not_active Application Discontinuation
- 2001-02-15 PT PT01920996T patent/PT1257281E/pt unknown
- 2001-02-15 PL PL01365239A patent/PL365239A1/xx unknown
- 2001-02-15 JP JP2001559475A patent/JP4975930B2/ja not_active Expired - Fee Related
- 2001-02-15 CN CNB018077455A patent/CN1268335C/zh not_active Expired - Fee Related
- 2001-02-15 KR KR1020027010417A patent/KR100811927B1/ko not_active IP Right Cessation
- 2001-02-15 ES ES07107588.1T patent/ES2528429T3/es not_active Expired - Lifetime
- 2001-02-15 CZ CZ20022799A patent/CZ20022799A3/cs unknown
- 2001-02-15 CA CA002395854A patent/CA2395854A1/en not_active Abandoned
- 2001-02-15 SK SK1149-2002A patent/SK287765B6/sk not_active IP Right Cessation
- 2001-02-15 NZ NZ52087701A patent/NZ520877A/xx not_active IP Right Cessation
- 2001-02-15 AU AU47988/01A patent/AU783142B2/en not_active Ceased
- 2001-02-15 SK SK1157-2002A patent/SK11572002A3/sk unknown
- 2001-02-15 IL IL15099001A patent/IL150990A0/xx unknown
- 2001-02-15 WO PCT/US2001/040148 patent/WO2001060379A1/en active Search and Examination
- 2001-02-15 YU YU61502A patent/YU61502A/sh unknown
- 2001-02-15 EP EP01910892A patent/EP1278528A4/en not_active Withdrawn
- 2001-02-15 CN CN01805036A patent/CN1420779A/zh active Pending
- 2001-02-15 HU HU0300912A patent/HUP0300912A2/hu unknown
- 2001-02-15 BR BR0108401-1A patent/BR0108401A/pt not_active IP Right Cessation
- 2001-02-15 RS RSP-2009/0086A patent/RS20090086A/sr unknown
- 2001-02-15 PL PL357945A patent/PL200140B1/pl unknown
- 2001-02-15 DE DE60131250T patent/DE60131250T8/de active Active
- 2001-02-15 AT AT01920996T patent/ATE377422T1/de active
- 2001-02-15 MX MXPA02007931A patent/MXPA02007931A/es active IP Right Grant
- 2001-02-15 MX MXPA02007932A patent/MXPA02007932A/es unknown
- 2001-02-15 ES ES01920996T patent/ES2295148T3/es not_active Expired - Lifetime
-
2002
- 2002-07-08 HR HR20020583A patent/HRP20020583A2/xx not_active Application Discontinuation
- 2002-07-30 IL IL150990A patent/IL150990A/en not_active IP Right Cessation
- 2002-08-07 HR HR20020657A patent/HRP20020657A2/hr not_active Application Discontinuation
- 2002-08-14 NO NO20023855A patent/NO329927B1/no not_active IP Right Cessation
- 2002-08-14 NO NO20023852A patent/NO20023852L/no not_active Application Discontinuation
-
2003
- 2003-05-19 HK HK03103531A patent/HK1051149A1/xx not_active IP Right Cessation
-
2007
- 2007-12-19 CY CY20071101614T patent/CY1107103T1/el unknown
-
2009
- 2009-01-29 JP JP2009018382A patent/JP5253204B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004509061A5 (ja) | ||
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2003526662A5 (ja) | ||
| JP2004504406A5 (ja) | ||
| JP2003526673A5 (ja) | ||
| WO2003063771A3 (en) | N4-acylcytosine nucleosides for treatment of viral iinfections | |
| JP2021100937A5 (ja) | ||
| JP2008514732A5 (ja) | ||
| JP2008521934A5 (ja) | ||
| JP2002543144A5 (ja) | ||
| JP2005508337A5 (ja) | ||
| RU95117097A (ru) | ПРИМЕНЕНИЕ ДИДЕЗОКСИ-АНАЛОГОВ НУКЛЕОЗИДОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, СПОСОБ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ, β -Z-5-ФТОР-2',3'-ДИДЕЗОКСИЦИТОЗИН И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ ПРОИЗВОДНЫЕ | |
| JP2003503449A5 (ja) | ||
| JP2003514025A5 (ja) | ||
| RU2002112248A (ru) | Лечение вирусных инфекций с использованием левовирина | |
| JPWO2021050956A5 (ja) | ||
| JPWO2019200005A5 (ja) | ||
| JP2003512421A5 (ja) | ||
| JP2004529158A5 (ja) | ||
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| JP2005509615A5 (ja) | ||
| JP2007516296A5 (ja) | ||
| JP2018131439A5 (ja) | ||
| JP2006510610A5 (ja) | ||
| JP2015509980A5 (ja) |